Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92609ArticlesСтатьиResearch ArticleFarmakoterapiya obostreniy khronicheskoy obstruktivnoy bolezni legkikh: sovremennyy vzglyad na antibakterial'nuyu terapiyuФармакотерапия обострений хронической обструктивной болезни легких: современный взгляд на антибактериальную терапиюTsoyA. NЦойА. НLazarevaN. BЛазареваН. БDemidovaG. VДемидоваГ. ВГОУ ВПО Московская медицинская академия им. И.М.Сеченова15032008103VOL 10, NO3 (2008)ТОМ 10, №3 (2008)444828122021Copyright ©; 2008, Consilium MedicumCopyright ©; 2008, ООО "Консилиум Медикум"2008Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/92609

Хроническая обструктивная болезнь легких (ХОБЛ) представляет собой одну из ведущих причин смертности в мире. Развитие обострений заболевания часто служит основной причиной обращений за медицинской помощью, госпитализаций и летальных исходов. Частота обострений является одним из наиболее важных факторов, определяющих качество жизни больных ХОБЛ, темпы прогрессирования заболевания и экономические потери [1]. Начиная с 1964 г. было опубликовано более 4000 научных статей, посвященных проблеме использования антибиотиков при ХОБЛ. Однако лишь ограниченное количество проведенных клинических исследований оказалось пригодным для включения в международные согласительные документы по лечению ХОБЛ [2]. Несмотря на издание ряда национальных и международных руководств, основывающихся на принципах доказательной медицины, ряд вопросов, касающихся проведения антибактериальной терапии при обострениях ХОБЛ, является предметом дискуссий. К таким вопросам относятся положение о ключевой роли бактерий в развитии обострений и определение клинических и биологических маркеров, позволяющих выявить различия между бактериальной и другими причинами обострений ХОБЛ, также о том, насколько эффективны разные антибактериальные препараты в сравнении друг с другом и плацебо, какой именно антибиотик должен быть назначен пациенту с обострением ХОБЛ

Miravitlles M, Zalacain R, Murio C et al. Speed of recovery from acute exacerbations of COPD after treatment with antimicrobials: results of a two - year study. Clin Drug Invest 2003; 23: 439–50.Miravitlles M, Torres A. No more equivalence trials for antibiotics in exacerbations of COPD, please. Chest 2004; 125: 811–3.Miravitlles M, Torres A. Antibiotics in exacerbations of COPD: lessons from the past. Eur Respir J 2004; 24: 896–7.Wilson R. Bacteria, antibiotics and COPD. Eur Respir J 2001; 17: 995–1007.Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. EurRespir J 1995; 8: 1333–8.Anthonison N.R. The British hypothesis revisited. Eur Respir J 2004; 23: 657–8.Murphy T.F., Sethi S. Bacteria infection in chronic obstruction pulmonary disease. Am Rev Respir Dis 1992; 146: 1067–83.Kanner R.E., Anthonisen N..R, Connett J.E. for the Lung Health Study Research Group. Lower respiratory illnesses promote FEV1 decline in current smokers but not exsmokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 358–64.Donaldson G.C., Seemungal T.A.R., Bhomik A, Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–52.Patel I.S., Seemungal T.A., Wilks M et al. Relationship between bacterial colonisation and the frequency, character and severity of COPD exacerbations. Thorax 2002; 57: 759–64.Sethi S, Evans N, Grant B, Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465–71.Stockley R.A., O\'Brien C, Pye A et al. Relationship of sputum colour to nature and outpatient management of acute exacerbations of COPD. Chest 2001; 117: 1638–45.Monso E, Rosell A.I., Boret G et al. Risk factors of lower airway bacterial colonization in chronic bronchitis. Eur Respir J 1999; 13: 338–42.Zalacain R, Sobradillo V, Amilibia J et al. Predispoing factors to bacterial colonisation in chronic obstructive pulmonary disease. Eur Respir J 1999; 13: 343–8.Bandi V, Jakubowycz M, Kinyon C et al. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non - typeable Haemophilus influenzae. FEMS Immunol Med Microbiol 2003; 37: 69–75.White A.J., Gompertz S, Bayley D.L. et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680–5.Sohy C, Pilette C, Niederman M.S., Sibille Y. Acute exacerbation of chronic obstructive pulmonary disease and antibiotics: whatstudies are still needed? Eur Respir J 2002; 19: 966–75.Saint S.K., Bent S, Vittinghoff E et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a metaanalysis. J Am Med Assoc 1995; 273: 957–60.Anthonisen N.R., Manfreda J, Warren C.P.W. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonarydisease. Ann Intern Med 1987; 106: 196–204.Allegra F, Blasi B, de Bernardi R, Cosentini P. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re - evaluation of previously published data of a placebo - controlled randomized study. Pulm Pharmacol Ther 2001; 14: 149–55.Chodosh S, Mc Carty J, Farkas S et al. Randomized, double - blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations ofchronic bronchitis. Clin Infect Dis 1998; 27: 722–9.Gotfried M.H., De Abate C.A., Fogarty C et al. Comparison of 5 - day, short course gatifloxacin therapy with 7 - day gatifloxacin therapy and 10 - day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin Ther 2001; 23: 97–107.Georgopoulos A, Borek M, Ridl W. Randomized, double - blind, double dummy study comparing the efficacy and safety of amoxycillin 1g bd with amoxycillin 500 mg td in the treatment of acute exacerbation of chronic bronchitis. J Antimicrob chemother 2001; 47: 67–76.Adler J.L., Jannetti W, Schneider D et al. Phase III, randomized, double - blind study of clarithromycin extended - release and immediaterelease formulations in the treatment of patients with acute exacerbation of chronic bronchitis. Clin Ther 2000; 22: 1410–20.File T, Schlemmer B, Garau J et al. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. J Chemother 2000; 12: 314–25.Mc Adoo M.A., Rice K, Gordon G.R., Sahn S.A. Comparison of ceftibuten once daily and amoxicillin/clavulanate three times daily in the treatment of acute exacerbations of chronic bronchitis. Clin Ther 1998; 20: 88–100.Langan C.E., Cranfield R, Breisch S, Pettit R. Randomized, double blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother 1997; 40 (Suppl. A): 63–72.Shah P.M., Maesen F.P.V., Dolmann A et al. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbations of chronic bronchitis: results of a randomized, double - blind study. J Antimicrob Chemother 1999; 43: 529–39.H.C. Neu and T.W. Chick. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections Chest 1993; 104: 1393–9.Wilson R, Kubin R, Ballin I et al. Five day moxifloxacin therapy compared with seven day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44: 501–13.Wilson R, Schentag J.J., Ball P, Mandell L.A. Comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long - term clinical outcomes. Clin Therap 2002; 24: 639–52.Wilson R, Allegra L, Huchon G et al. Short - term and longterm outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953–64.Ram F.S., Rodriguez-Roisin R, Barnes N.C. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006; 2: CD004403.Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2006) Disclosure forms for GOLD Committees are posted on the GOLD Website, www.goldcopd.orgMiravitlles M, Espinosa C, Fernandez-Laso E et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116 (1): 40–6.Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS positionpaper. Eur Respir J 2004; 23 (6): 932–46.